Please note: The information displayed on this page might be outdated.
Stemline Therapeutics, Inc.:
ELZONRIS, a commercial targeted therapy directed to IL-3 receptor (CD123), approved for BPDCN and ongoing trials in other indications; SL-801 an oral small molecule reversible inhibitor of XPO1 in Ph 1 trial; and SL-701 an immunotherapeutic that completed Ph 2 trial in pts w/2nd line GBM
US - Middle Atlantic
Marketed, Phase l or ll
Immunotherapy, Oncology, Rare Disease
500MM - 1B
Platform Technology, Small Molecule
750 Lexington Ave
New York, NY 10022
Top 10 Holders of Stemline Therapeutics, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by